Genocea Biosciences Inc Shares Close the Day 19.7% Higher - Daily Wrap
The company saw its shares close the day 19.7% higher than yesterday, with trading volume higher than its 30 day average.
Dec 25, 2021 by Kwhen Finance Editors
Genocea Biosciences Inc (GNCA) shares closed today 19.7% higher than it did at the end of yesterday. The stock is currently down 48.6% year-to-date, down 51.7% over the past 12 months, and down 96.7% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%.
Trading Activity
- Shares traded as high as $1.35 and as low as $0.91 this week.
- Shares closed 69.3% below its 52-week high and 36.8% above its 52-week low.
- Trading volume this week was 84.2% lower than the 10-day average and 56.9% lower than the 30-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
- MACD, a trend-following momentum indicator, indicates an upward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
- The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis
- The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis
- The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Genocea Biosciences Inc | 19.7 | -48.6 | -51.7 | -72.3 | 23.1 |
| Dow Jones Industrial Average | 0.6 | 19.5 | 21.0 | -1.6 | 22.0 |
| S&P 500 Index | 0.6 | 27.5 | 29.2 | -0.7 | 30.2 |
| Health Care | 0.5 | 22.4 | 24.2 | -0.3 | 26.5 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date lags the peer average by -351.5%
- The company's stock price performance over the past 12 months lags the peer average by -520.0%
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Genocea Biosciences Inc | GNCA | 0 | -48.6 | -51.7 | -72.3 | 23.1 |
| Peer Avg | N/A | 55.1 | 19.3 | 12.3 | -38.1 | 123.1 |
| Pfizer Inc. | PFE | 17.2 | 65.7 | 63.7 | -3.5 | 83.6 |
| Merck & Co Inc | MRK | 26.6 | -4.1 | -2.1 | -15.7 | 411.7 |
| Novavax, Inc. | NVAX | -12.5 | 59.0 | 37.0 | -44.3 | 69.4 |
| Agenus Inc | AGEN | 244.1 | 12.6 | 5.6 | -49.0 | 38.4 |
| iBio Inc. | IBIO | 0 | -36.7 | -42.7 | -77.7 | 12.5 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: